<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02556918</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00082180</org_study_id>
    <nct_id>NCT02556918</nct_id>
  </id_info>
  <brief_title>Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery</brief_title>
  <acronym>SITA-CABGDM</acronym>
  <official_title>Sitagliptin for the Prevention and Treatment of Hyperglycemia in Patients With Type 2 Diabetes Undergoing Cardiac Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether treatment with sitagliptin reduces the
      frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to
      determine whether treatment with sitagliptin is effective in maintaining blood sugar control
      in patients with type 2 diabetes (T2D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether treatment with sitagliptin reduces the
      frequency and severity of high blood sugar (hyperglycemia) and the need for continuous
      intravenous insulin infusion (CII) in the intensive care unit (ICU) in patients with type 2
      diabetes (T2D) undergoing coronary artery bypass graft (CABG) surgery. In addition, the study
      seeks to determine whether treatment with sitagliptin is effective in maintaining glycemic
      control and in preventing the need for subcutaneous (SC) insulin therapy in patients with T2D
      during the transition from intensive care unit (ICU) to regular floor in cardiac surgery
      patients with T2D.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">November 6, 2018</completion_date>
  <primary_completion_date type="Actual">November 6, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With Hyperglycemia in the Intensive Care Unit (ICU)</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Number of patients with blood glucose (BG) levels greater than 180 mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Persistent Hyperglycemia</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Number of patients with two consecutive fasting and/or pre-meal blood glucose (BG) greater than 180 mg/dl, or with average daily BG greater than 80 mg/dl who require rescue therapy with subcutaneous (SC) insulin after discontinuation of continuous intravenous insulin infusion (CII).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Continuous Intravenous Insulin Infusion (CII)</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Number of patients requiring CII to achieve a blood glucose level (BG) target between 150-200 mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Blood Glucose (BG) Concentration in the Intensive Care Unit (ICU)</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Mean blood glucose (BG) concentration of ICU patients during recovery period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total IV Insulin in ICU</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Total IV insulin in ICU during recovery period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Insulin Dose Per Day During Intensive Care Unit (ICU) Recovery</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Mean insulin infusion dose per day of ICU patients during recovery period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Continuous Intravenous Insulin Infusion (CII)</measure>
    <time_frame>Up to 48 hours (average time of discharge from ICU)</time_frame>
    <description>Total hours of continuous intravenous insulin infusion (CII)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Requiring Subcutaneous (SQ) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Number of patients requiring subcutaneous (SQ) insulin after discontinuation of continuous intravenous insulin infusion (CII)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Number of Days of Subcutaneous (SC) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)</measure>
    <time_frame>Up to 14 days (time of discharge from the hospital)</time_frame>
    <description>Median number of days patients requiring SC insulin after discontinuation of CII</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Post-operative Blood Glucose (BG) Concentration</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Mean post-operative blood glucose (BG) concentration during recovery period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Subcutaneous (SC) Insulin Taken in Intensive Care Unit (ICU)</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Total amount of SC insulin taken by ICU patients during recovery period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Subcutaneous (SC) Insulin in Intensive Care Unit (ICU) 48 Hours</measure>
    <time_frame>48 hours during recovery period</time_frame>
    <description>Amount of subcutaneous (SC) insulin in intensive care unit (ICU) 48 hours during recovery period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Hyperglycemia in Intensive Care Unit (ICU)</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Number of subjects with hyperglycemia (blood glucose greater than or equal to 300 mg/dL) in ICU recovery period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Hyperglycemia (Blood Glucose Greater Than or Equal to 300 mg/dL) in Non-ICU</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Number of subjects with hyperglycemia (blood glucose greater than or equal to 300 mg/dL) in non-ICU recovery period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hypoglycemic Events in Intensive Care Unit (ICU)</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Number of patients with events (blood glucose less than 70 mg/dL) in patients in intensive care unit (ICU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Hypoglycemic Events in Non-intensive Care Unit (ICU)</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Number of Patients With hypoglycemic events (blood glucose less than 70 mg/dL) in patients in non-intensive care unit (ICU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Severe Hypoglycemic Events in Intensive Care Unit (ICU)</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Number of Patients With severe hypoglycemia (blood glucose less than 40 mg/dL) in patients in intensive care unit (ICU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Severe Hypoglycemic Events in Non-intensive Care Unit (ICU)</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Number of Patients With hypoglycemic events (blood glucose less than 40 mg/dL) in patients in non-intensive care unit (ICU).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite of Perioperative Complications</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Number of perioperative complications including hospital mortality, infection,acute renal failure, and acute mycordial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Intubation</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Duration that patients required to be intubated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit (ICU) Stay</measure>
    <time_frame>2 days (average time of discharge from ICU)</time_frame>
    <description>Total number of days spent in intensive care unit (ICU)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Length of Hospital Stay</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Total number of days spent in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Intensive Care Unit (ICU) Readmission</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Number of re-admissions to intensive care unit during the same hospital course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cerebrovascular Events</measure>
    <time_frame>10 days (average time of discharge from the hospital)</time_frame>
    <description>Number of cerebrovascular events including permanent stroke and reversible ischemic neurologic deficit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Readmitted to the Hospital</measure>
    <time_frame>30 days</time_frame>
    <description>Number of subjects readmitted to the hospital within 30 days (all-cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Returning to the ER Within 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>Number of subjects returning to the ER within 30 days (all-cause).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">202</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Sitagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects undergoing cardiac surgery with type 2 diabetes (T2D) will be randomized to receive one tablet of sitagliptin once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive sitagliptin and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
Interventions:
Drug: Sitagliptin Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects undergoing cardiac surgery with type 2 diabetes will be randomized to receive one tablet of placebo once a day.Subjects with stress hyperglycemia (defined as a blood glucose (BG) greater than 180 mg/dL) in the intensive care unit (ICU) will continue to receive a placebo and will be started on continuous intravenous insulin (Regular Human Insulin) adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Additionally, once moved to the regular floors and out of ICU, the subjects can receive insulin glargine, insulin lispro, and/or insulin aspart depending on the blood glucose level.
Interventions:
Drug: Placebo Drug: Regular Human Insulin Drug: Insulin glargine Drug: Supplemental insulin (Insulin lispro) Drug: Supplemental insulin (Insulin aspart)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.</description>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One pill daily starting one day prior to surgery until discharge from the hospital.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular Human Insulin</intervention_name>
    <description>Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Novolin-R</other_name>
    <other_name>Humulin-R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine</intervention_name>
    <description>Patients that required continuous insulin infusion (CII) at a rate &gt;1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.
The total daily insulin dose will be adjusted as follow:
Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between &gt;180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG &gt;241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG &lt;100 mg/dl: stop basal</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplemental insulin (Insulin lispro)</intervention_name>
    <description>Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin lispro
BG between 221-260 mg/dL; 3-5 units of insulin lispro
BG between 261-300 mg/dL; 4-6 units of insulin lispro
BG between 301-350 mg/dL; 5-7 units of insulin lispro
BG between 351-400 mg/dL; 6-8 units of insulin lispro
BG greater than 400 mg/dL; 7-9 units of insulin lispro</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Humalog</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Supplemental insulin (Insulin aspart)</intervention_name>
    <description>Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin aspart
BG between 221-260 mg/dL; 3-5 units of insulin aspart
BG between 261-300 mg/dL; 4-6 units of insulin aspart
BG between 301-350 mg/dL; 5-7 units of insulin aspart
BG between 351-400 mg/dL; 6-8 units of insulin aspart
BG greater than 400 mg/dL; 7-9 units of insulin aspart</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sitagliptin</arm_group_label>
    <other_name>Novolog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The ability to provide informed consent

          -  Ages 18 to 80 years old

          -  Male or female

          -  Scheduled to undergo cardiac surgery

          -  Type 2 Diabetes treated with diet, oral agents,

        Exclusion Criteria:

          -  Severely impaired kidney function (glomeruler filtration rate (GFR ) less than 30
             ml/min)

          -  Clinically significant liver failure

          -  Imminent risk of death (brain death or cardiac standstill)

          -  Gastrointestinal obstruction or adynamic ileus

          -  Expected to require gastrointestinal suction

          -  Clinically relevant pancreatic or gallbladder disease

          -  Using oral or injectable corticosteroid

          -  Mental condition rendering the subject unable to understand the nature, scope, and
             possible consequences of the study

          -  Female subjects are pregnant or breast feeding at time of enrollment into the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Umpierrez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univeristy Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2015</study_first_posted>
  <results_first_submitted>November 6, 2019</results_first_submitted>
  <results_first_submitted_qc>December 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">December 23, 2019</results_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Guillermo Umpierrez, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Coronary artery bypass graft surgery (CABG)</keyword>
  <keyword>Type 2 Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT02556918/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>One participant died during hospital admission before receiving study medication.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin</title>
          <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin</title>
          <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="101"/>
            <count group_id="B3" value="201"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="9.1"/>
                    <measurement group_id="B2" value="63.3" spread="7.8"/>
                    <measurement group_id="B3" value="63.8" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Hyperglycemia in the Intensive Care Unit (ICU)</title>
        <description>Number of patients with blood glucose (BG) levels greater than 180 mg/dl</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Insulin glargine: Patients that required continuous insulin infusion (CII) at a rate &gt;1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day)
Supplemental insulin (Insulin aspart): Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hyperglycemia in the Intensive Care Unit (ICU)</title>
          <description>Number of patients with blood glucose (BG) levels greater than 180 mg/dl</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Persistent Hyperglycemia</title>
        <description>Number of patients with two consecutive fasting and/or pre-meal blood glucose (BG) greater than 180 mg/dl, or with average daily BG greater than 80 mg/dl who require rescue therapy with subcutaneous (SC) insulin after discontinuation of continuous intravenous insulin infusion (CII).</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Persistent Hyperglycemia</title>
          <description>Number of patients with two consecutive fasting and/or pre-meal blood glucose (BG) greater than 180 mg/dl, or with average daily BG greater than 80 mg/dl who require rescue therapy with subcutaneous (SC) insulin after discontinuation of continuous intravenous insulin infusion (CII).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Continuous Intravenous Insulin Infusion (CII)</title>
        <description>Number of patients requiring CII to achieve a blood glucose level (BG) target between 150-200 mg/dl</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Continuous Intravenous Insulin Infusion (CII)</title>
          <description>Number of patients requiring CII to achieve a blood glucose level (BG) target between 150-200 mg/dl</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Blood Glucose (BG) Concentration in the Intensive Care Unit (ICU)</title>
        <description>Mean blood glucose (BG) concentration of ICU patients during recovery period.</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Blood Glucose (BG) Concentration in the Intensive Care Unit (ICU)</title>
          <description>Mean blood glucose (BG) concentration of ICU patients during recovery period.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148.7" spread="15.8"/>
                    <measurement group_id="O2" value="149.8" spread="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total IV Insulin in ICU</title>
        <description>Total IV insulin in ICU during recovery period.</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Total IV Insulin in ICU</title>
          <description>Total IV insulin in ICU during recovery period.</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.43" spread="123.44"/>
                    <measurement group_id="O2" value="95.68" spread="118.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Insulin Dose Per Day During Intensive Care Unit (ICU) Recovery</title>
        <description>Mean insulin infusion dose per day of ICU patients during recovery period.</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Insulin Dose Per Day During Intensive Care Unit (ICU) Recovery</title>
          <description>Mean insulin infusion dose per day of ICU patients during recovery period.</description>
          <units>unit/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9" spread="36.1"/>
                    <measurement group_id="O2" value="46.4" spread="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Continuous Intravenous Insulin Infusion (CII)</title>
        <description>Total hours of continuous intravenous insulin infusion (CII)</description>
        <time_frame>Up to 48 hours (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Continuous Intravenous Insulin Infusion (CII)</title>
          <description>Total hours of continuous intravenous insulin infusion (CII)</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="27.6"/>
                    <measurement group_id="O2" value="27.7" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Requiring Subcutaneous (SQ) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)</title>
        <description>Number of patients requiring subcutaneous (SQ) insulin after discontinuation of continuous intravenous insulin infusion (CII)</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <population>Some patients were not transitioned to SQ insulin because they stayed on CII due to complications, these patients were taken off the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Requiring Subcutaneous (SQ) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)</title>
          <description>Number of patients requiring subcutaneous (SQ) insulin after discontinuation of continuous intravenous insulin infusion (CII)</description>
          <population>Some patients were not transitioned to SQ insulin because they stayed on CII due to complications, these patients were taken off the analysis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Number of Days of Subcutaneous (SC) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)</title>
        <description>Median number of days patients requiring SC insulin after discontinuation of CII</description>
        <time_frame>Up to 14 days (time of discharge from the hospital)</time_frame>
        <population>Some patients were not transitioned to SQ insulin because they stayed on CII due to complications, these patients were taken off the analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Number of Days of Subcutaneous (SC) Insulin After Discontinuation of Continuous Intravenous Insulin Infusion (CII)</title>
          <description>Median number of days patients requiring SC insulin after discontinuation of CII</description>
          <population>Some patients were not transitioned to SQ insulin because they stayed on CII due to complications, these patients were taken off the analysis</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="0" upper_limit="14"/>
                    <measurement group_id="O2" value="4" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Post-operative Blood Glucose (BG) Concentration</title>
        <description>Mean post-operative blood glucose (BG) concentration during recovery period.</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Post-operative Blood Glucose (BG) Concentration</title>
          <description>Mean post-operative blood glucose (BG) concentration during recovery period.</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.2" spread="29.0"/>
                    <measurement group_id="O2" value="156.5" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Subcutaneous (SC) Insulin Taken in Intensive Care Unit (ICU)</title>
        <description>Total amount of SC insulin taken by ICU patients during recovery period.</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Subcutaneous (SC) Insulin Taken in Intensive Care Unit (ICU)</title>
          <description>Total amount of SC insulin taken by ICU patients during recovery period.</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="6.4"/>
                    <measurement group_id="O2" value="2.2" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Subcutaneous (SC) Insulin in Intensive Care Unit (ICU) 48 Hours</title>
        <description>Amount of subcutaneous (SC) insulin in intensive care unit (ICU) 48 hours during recovery period.</description>
        <time_frame>48 hours during recovery period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Subcutaneous (SC) Insulin in Intensive Care Unit (ICU) 48 Hours</title>
          <description>Amount of subcutaneous (SC) insulin in intensive care unit (ICU) 48 hours during recovery period.</description>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" spread="3.8"/>
                    <measurement group_id="O2" value="1.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Hyperglycemia in Intensive Care Unit (ICU)</title>
        <description>Number of subjects with hyperglycemia (blood glucose greater than or equal to 300 mg/dL) in ICU recovery period.</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hyperglycemia in Intensive Care Unit (ICU)</title>
          <description>Number of subjects with hyperglycemia (blood glucose greater than or equal to 300 mg/dL) in ICU recovery period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Hyperglycemia (Blood Glucose Greater Than or Equal to 300 mg/dL) in Non-ICU</title>
        <description>Number of subjects with hyperglycemia (blood glucose greater than or equal to 300 mg/dL) in non-ICU recovery period.</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Hyperglycemia (Blood Glucose Greater Than or Equal to 300 mg/dL) in Non-ICU</title>
          <description>Number of subjects with hyperglycemia (blood glucose greater than or equal to 300 mg/dL) in non-ICU recovery period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hypoglycemic Events in Intensive Care Unit (ICU)</title>
        <description>Number of patients with events (blood glucose less than 70 mg/dL) in patients in intensive care unit (ICU).</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hypoglycemic Events in Intensive Care Unit (ICU)</title>
          <description>Number of patients with events (blood glucose less than 70 mg/dL) in patients in intensive care unit (ICU).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Hypoglycemic Events in Non-intensive Care Unit (ICU)</title>
        <description>Number of Patients With hypoglycemic events (blood glucose less than 70 mg/dL) in patients in non-intensive care unit (ICU).</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Hypoglycemic Events in Non-intensive Care Unit (ICU)</title>
          <description>Number of Patients With hypoglycemic events (blood glucose less than 70 mg/dL) in patients in non-intensive care unit (ICU).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Severe Hypoglycemic Events in Intensive Care Unit (ICU)</title>
        <description>Number of Patients With severe hypoglycemia (blood glucose less than 40 mg/dL) in patients in intensive care unit (ICU).</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Severe Hypoglycemic Events in Intensive Care Unit (ICU)</title>
          <description>Number of Patients With severe hypoglycemia (blood glucose less than 40 mg/dL) in patients in intensive care unit (ICU).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Severe Hypoglycemic Events in Non-intensive Care Unit (ICU)</title>
        <description>Number of Patients With hypoglycemic events (blood glucose less than 40 mg/dL) in patients in non-intensive care unit (ICU).</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Severe Hypoglycemic Events in Non-intensive Care Unit (ICU)</title>
          <description>Number of Patients With hypoglycemic events (blood glucose less than 40 mg/dL) in patients in non-intensive care unit (ICU).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite of Perioperative Complications</title>
        <description>Number of perioperative complications including hospital mortality, infection,acute renal failure, and acute mycordial infarction.</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Perioperative Complications</title>
          <description>Number of perioperative complications including hospital mortality, infection,acute renal failure, and acute mycordial infarction.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Intubation</title>
        <description>Duration that patients required to be intubated</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Intubation</title>
          <description>Duration that patients required to be intubated</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.1"/>
                    <measurement group_id="O2" value="0.7" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit (ICU) Stay</title>
        <description>Total number of days spent in intensive care unit (ICU)</description>
        <time_frame>2 days (average time of discharge from ICU)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Unit (ICU) Stay</title>
          <description>Total number of days spent in intensive care unit (ICU)</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="3.2"/>
                    <measurement group_id="O2" value="2.2" lower_limit="1.4" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Length of Hospital Stay</title>
        <description>Total number of days spent in hospital</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Length of Hospital Stay</title>
          <description>Total number of days spent in hospital</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="6" upper_limit="12"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Intensive Care Unit (ICU) Readmission</title>
        <description>Number of re-admissions to intensive care unit during the same hospital course.</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Intensive Care Unit (ICU) Readmission</title>
          <description>Number of re-admissions to intensive care unit during the same hospital course.</description>
          <units>readmissions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cerebrovascular Events</title>
        <description>Number of cerebrovascular events including permanent stroke and reversible ischemic neurologic deficit</description>
        <time_frame>10 days (average time of discharge from the hospital)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cerebrovascular Events</title>
          <description>Number of cerebrovascular events including permanent stroke and reversible ischemic neurologic deficit</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Readmitted to the Hospital</title>
        <description>Number of subjects readmitted to the hospital within 30 days (all-cause).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Readmitted to the Hospital</title>
          <description>Number of subjects readmitted to the hospital within 30 days (all-cause).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Returning to the ER Within 30 Days</title>
        <description>Number of subjects returning to the ER within 30 days (all-cause).</description>
        <time_frame>30 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin</title>
            <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Returning to the ER Within 30 Days</title>
          <description>Number of subjects returning to the ER within 30 days (all-cause).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>one month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin</title>
          <description>Sitagliptin: Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: One pill daily starting one day prior to surgery until discharge from the hospital</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Miocardial Infarction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="66" subjects_affected="27" subjects_at_risk="100"/>
                <counts group_id="E2" events="50" subjects_affected="25" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Re-admittion to ICU</sub_title>
                <counts group_id="E1" events="14" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Re-intubation</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Hospital readmissions for other reasons</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Readmission due to surgical site infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="57" subjects_affected="20" subjects_at_risk="100"/>
                <counts group_id="E2" events="34" subjects_affected="16" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Surgical Site Bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Guillermo Umpierrez</name_or_title>
      <organization>Emory University</organization>
      <phone>404-778-1665</phone>
      <email>GEUMPIE@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

